Frank Floca
Psychiatry · Austin, TXNPI 1962443382
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,400 of the $37,651 with a category attached, or 64.8%. Otsuka America Pharmaceutical, Inc. accounts for 78.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $11,406 and has fallen 76.1% since, to $2,729 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 382 payments — averaging $98.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$29K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$899
- Avanir Pharmaceuticals, Inc.$360
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$24,40065%
- Travel & lodging$2,6387%
- Food & beverage$10,53428%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 102 | $29,386 |
| Alkermes, Inc. | 82 | $2,362 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 42 | $1,444 |
| Teva Pharmaceuticals USA, Inc. | 60 | $1,140 |
| Neurocrine Biosciences, Inc. | 17 | $899 |
| Avanir Pharmaceuticals, Inc. | 6 | $360 |
| Vanda Pharmaceuticals Inc. | 14 | $302 |
| Johnson & Johnson | 15 | $297 |
| Acadia Pharmaceuticals Inc | 6 | $292 |
| Lundbeck LLC | 12 | $225 |
| E.r. Squibb & Sons, L.L.C. | 6 | $210 |
| AbbVie(2 entities) | 5 | $207 |
| Janssen Scientific Affairs, LLC | 1 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $87 |
| Indivior Inc. | 3 | $65 |
| Supernus Pharmaceuticals, Inc. | 3 | $58 |
| Boehringer Ingelheim | 1 | $58 |
| Corium, LLC | 3 | $55 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $37 |
| Alpha Cognition USA, Inc. | 1 | $36 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$27,557
- LYBALVI$2,032
- ARISTADA$1,859
- CAPLYTA$750
- ABILIFY MAINTENA$650
- INGREZZA$291
- AUSTEDO$240
- NUPLAZID$229
- NUEDEXTA$218
- ARISTADA INITIO$216
- VRAYLAR$125
- ABILIFY ASIMTUFII$121
- INVEGA SUSTENNA$120
- COBENFY$112
How this compares
$37,651 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 32 | $95,062 |
| Risperdal ConstaRisperidone Microspheres | 22 | $42,873 |
| Abilify MaintenaAripiprazole | 13 | $35,873 |
| Oxcarbazepine | 148 | $13,443 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 38 | $11,417 |
| Naltrexone Hcl | 30 | $9,242 |
| Rivastigmine | 36 | $8,690 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $7,675 |
| Memantine Hcl | 138 | $6,352 |
| Clozapine | 48 | $5,561 |
| Lisdexamfetamine Dimesylate | 19 | $4,827 |
| Focalin XrDexmethylphenidate Hcl | 18 | $4,539 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 28 | $4,470 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 19 | $3,971 |
| BelsomraSuvorexant | 14 | $3,879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $297 | $137,93654 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $29,386 | $35,87313 claims |
| AbbVieNamzaric | $207 | $7,67512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Austin
- Arvinder Pal WaliaAustin$2.5M
- Charles NemeroffAustin$429K
- Divyansu PatelAustin$50K
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.